NervGen Pharma Corp. (NGEN.V)

CAD 2.46

(-7.17%)

Total Debt Summary of NervGen Pharma Corp.

NervGen Pharma Corp.'s latest annual total debt in 2023 was 197.19 Thousand CAD , down -30.43% from previous year.
NervGen Pharma Corp.'s latest quarterly total debt in 2024 Q2 was 152.08 Thousand CAD , down -13.0% from previous quarter.
NervGen Pharma Corp. reported annual total debt of 283.45 Thousand CAD in 2022, down 0.0% from previous year.
NervGen Pharma Corp. reported annual total debt of - CAD in 2021, down 0.0% from previous year.
NervGen Pharma Corp. reported quarterly total debt of 152.08 Thousand CAD for 2024 Q2, down -13.0% from previous quarter.
NervGen Pharma Corp. reported quarterly total debt of 197.19 Thousand CAD for 2023 FY, down -30.43% from previous quarter.

Annual Total Debt Chart of NervGen Pharma Corp. (2023 - 2017)

Historical Annual Total Debt of NervGen Pharma Corp. (2023 - 2017)

Year	Total Debt	Total Debt Growth
2023	197.19 Thousand CAD	-30.43%
2022	283.45 Thousand CAD	0.0%
2021	- CAD	0.0%
2020	- CAD	0.0%
2019	- CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	174.8 Thousand CAD	-11.35%
2024 Q2	152.08 Thousand CAD	-13.0%
2023 FY	197.19 Thousand CAD	-30.43%
2023 Q3	219.24 Thousand CAD	-9.02%
2023 Q1	262.37 Thousand CAD	-7.44%
2023 Q2	240.96 Thousand CAD	-8.16%
2023 Q4	197.19 Thousand CAD	-10.06%
2022 Q1	- CAD	0.0%
2022 FY	283.45 Thousand CAD	0.0%
2022 Q2	324.69 Thousand CAD	0.0%
2022 Q4	283.45 Thousand CAD	-6.83%
2022 Q3	304.22 Thousand CAD	-6.3%
2021 Q1	- CAD	0.0%
2021 FY	- CAD	0.0%
2021 Q4	- CAD	0.0%
2021 Q3	- CAD	0.0%
2021 Q2	- CAD	0.0%
2020 FY	- CAD	0.0%
2020 Q2	- CAD	0.0%
2020 Q4	- CAD	0.0%
2020 Q3	- CAD	0.0%
2020 Q1	- CAD	0.0%
2019 Q1	- CAD	0.0%
2019 FY	- CAD	0.0%
2019 Q4	- CAD	0.0%
2019 Q3	- CAD	0.0%
2019 Q2	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q4	- CAD	0.0%
2017 FY	- CAD	0.0%

Peer Total Debt Comparison of NervGen Pharma Corp.

Name	Total Debt	Total Debt Difference
Arch Biopartners Inc.	5.01 Million CAD	96.069%
Covalon Technologies Ltd.	1.56 Million CAD	87.38%
Hemostemix Inc.	4.32 Million CAD	95.437%
Universal Ibogaine Inc.	1.73 Million CAD	88.652%
Kane Biotech Inc.	8.27 Million CAD	97.617%
MedMira Inc.	9.27 Million CAD	97.873%
Marvel Biosciences Corp.	1 Million CAD	80.281%
XORTX Therapeutics Inc.	15.17 Thousand CAD	-1199.269%